The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.
Pyrilutamide and its effectiveness for treating hair loss, with advice from other users cautioning to wait at least 6 months before expecting any results. Treatments discussed include finasteride and minoxidil.
A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
OP noticed an increase in DHT levels after 5 months of using finasteride and is unsure if the drug is effective or if other factors like stress or vitamins are influencing the results. Users suggest testing the medication for authenticity, consulting a doctor, and possibly trying a different brand or dosage.
Research and science related to a minor improvement in hair growth caused by the use of verteporfin, as well as potential treatments such as Minoxidil, Finasteride, and RU58841.
RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.
The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
Reducing the dose of RU58841 from 25mg to 7.5mg topically helped minimize heart palpitations. Users discussed the cardiac effects of RU58841 and minoxidil, noting that no treatment is completely free of side effects.
Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.
Switching from finasteride to a generic dutasteride led to unexpectedly high DHT levels, prompting a switch to a reputed brand and consideration of softgel capsules for better absorption. The user plans to retest DHT levels and may return to finasteride if issues persist.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
A user increased their finasteride dosage from 0.5 mg to 1 mg due to ongoing hair miniaturization, despite some improvement. They are considering dutasteride and have not used minoxidil, but are cautious about potential side effects.
A user experienced increased pimples and cysts after two years on dutasteride, possibly due to hormonal changes. Suggestions included seeing an endocrinologist, using supplements like boron and DIM, adjusting diet, and reducing body fat to manage side effects.
The user shared their experience with taking 30g of creatine daily, noting no hair loss and improved physical performance, but minimal mental performance benefits. They also use 1.25mg of finasteride every other day.
PP405 shows potential for hair growth by increasing terminal hair and converting vellus hairs, but results are modest and more waiting is needed. It complements existing treatments like minoxidil and finasteride, but won't replace them.
The user increased finasteride to 1mg daily, stopped using ketoconazole and pyrithione zinc shampoos, and started using regular pH balanced shampoo with tea tree oil, rosemary/peppermint oil, and microneedling. They are now seeing new hair regrowth at the hairline and temples.
Reducing scalp DHT doesn't directly correlate with preventing hair miniaturization, as different follicles have varying sensitivity levels. Dutasteride at 0.5 mg and 2.5 mg shows minimal visual difference in hair regrowth, with side effects being a consideration for higher doses.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.
A 22-year-old male shared his positive experience using 1 mg finasteride daily for two years, noting significant hair thickening and texture improvement without side effects. Other users discussed their own hair loss treatments, including finasteride and minoxidil, and shared encouragement and advice.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
Ketoconazole is no longer sold in the UK, and pharmacies have replaced it with non-ketoconazole options. Users are discussing its availability and possible alternatives.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.